Reported Earlier, CG Oncology Prices $204.4M Public Offering Of 8M Common Shares At $28/Share
Reported Earlier, CG Oncology Prices $204.4M Public Offering Of 8M Common Shares At $28/Share
CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the pricing of its public offering of 8,000,000 shares of its common stock, 7,300,000 of which are being offered by CG Oncology and 700,000 of which are being offered by an existing stockholder of CG Oncology, each at a public offering price of $28.00 per share. The gross proceeds to CG Oncology from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $204.4 million
CG Oncology, Inc.（纳斯达克：CGON）是一家处于后期临床阶段的生物制药公司，专注于开发和商业化一种潜在的可替代膀胱保存治疗方案，旨在帮助患有膀胱癌的患者。今天，公司宣布其公开发行的8,000,000股普通股的定价，其中7,300,000股由CG Oncology提供，700,000股由CG Oncology的一位现有股东提供，公开发行价格为每股28.00美元。CG Oncology从此次发行中获得的总收益为20440万，在扣除承销折扣、佣金和其他发行费用之前。
